Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Down 5.26%
As of Wednesday, September 23, Gyre Therapeutics, Inc.’s GYRE share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Commentary & Analysis
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 7.31%
As of Thursday, September 17, Gyre Therapeutics, Inc.’s GYRE share price has surged by 7.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Is Gyre Therapeutics, Inc. (GYRE) Overvalued?
We dive into why Gyre Therapeutics, Inc. (GYRE) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 5.77%
As of Tuesday, August 04, Gyre Therapeutics, Inc.’s GYRE share price has surged by 5.77%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 5.91%
As of Monday, August 03, Gyre Therapeutics, Inc.’s GYRE share price has surged by 5.91%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $779.3 | $257.9 | 42% |
|
| Shares Out (Mil) | 100.6 | 54.3 | 62% |
|
| Institutional Ownership | 58.8% | 92.9% | 38% |
|
| Float (Mil) | 35.9 | 41.4 | 40% |
|
| Beta | 4.83 | 0.95 | 99% |
|
| Avg Daily Volume (000s) | 290 | 674 | 48% |
|
| Price Change (52-week) |
(0.3%) | 51.5% | 51% |
|
| Growth | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.073) | ($0.400) | ($0.235) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 2 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (39.2%) | (1,918%) | 7,900% | |
| Financials | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $110 | $37 | 27% |
|
| Net Income (TTM) (Mil) | ($21) | ($43) | 23% |
|
| EPS (TTM) | ($0.212) | ($1.600) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($32) | 25% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | $2 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $786 | $174 | 38% |
|
| Valuation | GYRE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.21 | 2.51 | 86% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 93.8% | 68.9% | 95% |
|
| Net Margin | (19.3%) | (72.5%) | 17% |
|
| ROA | (12.1%) | (47.7%) | 24% |
|
| ROE | (21.2%) | (54.9%) | 23% |
|
| Liabilities to Assets | 17.2% | 29.1% | 11% |
|
| F-Score | 1 | 3 | na |
|
Gyre Therapeutics, Inc. did not pass any screens on 9/25/2026.
